Series B Potential Clinomic recently closed a €23M Series B funding round in April 2025, indicating strong investor confidence and growing scale. This creates an opportunity to engage with a company undergoing expansion, procurement of scaling healthcare IT solutions, and potential upsell of enterprise-grade platforms, data analytics, and integration services.

AI in ICUs With a history of AI-driven intensive care solutions and notable milestones such as Mona, an intelligent bedside/telemedicine offering, Clinomic is positioned to adopt or expand AI-powered monitoring, decision support, and remote patient management tools across hospital networks.

Digital Transformation Clinomic emphasizes intelligent, efficient, and resource-driven digital transformation in healthcare, suggesting opportunities for implementing workflow automation, BPMN-based process optimization, and interoperability layers to modernize hospital operations and care delivery.

Geographic Growth As Aachen-based Clinomic achieves notable funding and international media coverage, there is potential to target European hospital systems and health networks seeking innovative medtech partners with a proven growth trajectory and scalable deployments.

Strategic Partnerships Clinomic’s tech stack and emphasis on patient outcomes, combined with a history of awards and spin-off origin from RWTH Aachen University Hospital, indicates receptivity to collaborations with healthtech integrators, payer pilots, and research institutions for co-development and large-scale pilots.